AU · rank #20 · 2026-09-04
AMLX
NASDAQ · $4.14B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.621 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.11 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 0 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.171 |
| Analyst upside Consensus target $42.36 | +24.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +94.63% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.57 |
| Gross margin TTM | +13661.5% |
| 52w high | $41.14 |
| Market cap (USD) | $4.14B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Amylyx Pharmaceuticals is a late-stage rare-disease biotech with no commercial revenue, whose entire near-term value rests on avexitide, a first-in-class GLP-1 receptor antagonist that just posted positive Phase 3 LUCIDITY data in post-bariatric hypoglycemia.
Rationale
The analyst_upside strategy is reinforced here because the positive LUCIDITY readout on August 18 triggered a 45%-plus share move and six analyst target raises in 30 days, yet the stock still screens with 24.7% upside to consensus target and a strong 4.57/5 rating, suggesting analysts are still ratcheting estimates upward rather than fully pricing the approval pathway.
Material risks
- 1Single-asset concentration in avexitide means any adverse FDA feedback, a Complete Response Letter, or a safety signal in the Expanded Access Program would collapse the thesis entirely with no commercial revenue backstop.
- 2The 87.3% analyst target dispersion signals deep disagreement on peak sales and approval probability, and the freshly priced 14.1 million-share equity offering at $35.50 creates near-term overhang and dilution pressure against a stock that just ran 45%.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.